Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2011 1
2016 1
2017 1
2018 2
2020 3
2021 3
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
The change from baseline in the CDR-SB score at week 116 was 3.35 with gantenerumab and 3.65 with placebo in the GRADUATE I trial (difference, -0.31; 95% confidence interval [CI], -0.66 to 0.05; P = 0.10) and was 2.82 with gantenerumab and 3.01 with placebo in the GRADUATE …
The change from baseline in the CDR-SB score at week 116 was 3.35 with gantenerumab and 3.65 with placebo in the GRADUATE I trial (differenc …
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.
Banerjee S, High J, Stirling S, Shepstone L, Swart AM, Telling T, Henderson C, Ballard C, Bentham P, Burns A, Farina N, Fox C, Francis P, Howard R, Knapp M, Leroi I, Livingston G, Nilforooshan R, Nurock S, O'Brien J, Price A, Thomas AJ, Tabet N. Banerjee S, et al. Lancet. 2021 Oct 23;398(10310):1487-1497. doi: 10.1016/S0140-6736(21)01210-1. Lancet. 2021. PMID: 34688369 Free PMC article. Clinical Trial.
Mean CMAI scores at 12 weeks were not significantly different between participants receiving mirtazapine and participants receiving placebo (adjusted mean difference -1.74, 95% CI -7.17 to 3.69; p=0.53). The number of controls with adverse events (65 [64%] of 102 controls) …
Mean CMAI scores at 12 weeks were not significantly different between participants receiving mirtazapine and participants receiving placebo …
Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).
Winter-van Rossum I, Weiser M, Galderisi S, Leucht S, Bitter I, Glenthøj B, Hasan A, Luykx J, Kupchik M, Psota G, Rocca P, Stefanis N, Teitelbaum A, Bar Haim M, Leucht C, Kemmler G, Schurr T; EULAST Study Group; Davidson M, Kahn RS, Fleischhacker WW. Winter-van Rossum I, et al. Lancet Psychiatry. 2023 Mar;10(3):197-208. doi: 10.1016/S2215-0366(23)00005-6. Epub 2023 Jan 27. Lancet Psychiatry. 2023. PMID: 36716759 Clinical Trial.
Cox regression analyses showed that treatment discontinuation for any cause did not differ between the two combined treatment groups (hazard ration [HR] 1.16, 95% CI 0.94-1.43, p=0.18). No significant difference was found in the time to all-cause discontinuation between th …
Cox regression analyses showed that treatment discontinuation for any cause did not differ between the two combined treatment groups (hazard …
A comparative study of the effect of the Time for Dementia programme on medical students.
Banerjee S, Jones C, Wright J, Grosvenor W, Hebditch M, Hughes L, Feeney Y, Farina N, Mackrell S, Nilforooshan R, Fox C, Bremner S, Daley S. Banerjee S, et al. Int J Geriatr Psychiatry. 2021 Jul;36(7):1011-1019. doi: 10.1002/gps.5532. Epub 2021 Mar 28. Int J Geriatr Psychiatry. 2021. PMID: 33686788 Free PMC article.
RESULTS: In an adjusted multilevel model (intervention group n = 274, control n = 112), there was strong evidence supporting improvements for Time for Dementia participants in: total Approaches to Dementia Questionnaire score (coefficient: 2.19, p = 0.003) and its person-c …
RESULTS: In an adjusted multilevel model (intervention group n = 274, control n = 112), there was strong evidence supporting improvements fo …
Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT.
Howard R, Zubko O, Gray R, Bradley R, Harper E, Kelly L, Pank L, O’Brien J, Fox C, Tabet N, Livingston G, Bentham P, McShane R, Burns A, Ritchie C, Reeves S, Lovestone S, Ballard C, Noble W, Wilcock G, Nilforooshan R. Howard R, et al. Southampton (UK): NIHR Journals Library; 2020 Apr. Southampton (UK): NIHR Journals Library; 2020 Apr. PMID: 32338849 Free Books & Documents. Review.

Significantly fewer participants completed treatment with 400 mg of minocycline [29% (53/184)] than 200 mg [62% (112/181)] or placebo [64% (114/179)] (p < 0.0001), mainly because of gastrointestinal symptoms (p = 0.0008), dermatological side effects (p = 0

…
Significantly fewer participants completed treatment with 400 mg of minocycline [29% (53/184)] than 200 mg [62% (112/181)] or placebo [64% ( …
TIHM: An open dataset for remote healthcare monitoring in dementia.
Palermo F, Chen Y, Capstick A, Fletcher-Loyd N, Walsh C, Kouchaki S, True J, Balazikova O, Soreq E, Scott G, Rostill H, Nilforooshan R, Barnaghi P. Palermo F, et al. Sci Data. 2023 Sep 9;10(1):606. doi: 10.1038/s41597-023-02519-y. Sci Data. 2023. PMID: 37689815 Free PMC article.
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.
Howard R, Cort E, Bradley R, Harper E, Kelly L, Bentham P, Ritchie C, Reeves S, Fawzi W, Livingston G, Sommerlad A, Oomman S, Nazir E, Nilforooshan R, Barber R, Fox C, Macharouthu A, Ramachandra P, Pattan V, Sykes J, Curran V, Katona C, Dening T, Knapp M, Romeo R, Gray R. Howard R, et al. Health Technol Assess. 2018 Nov;22(67):1-62. doi: 10.3310/hta22670. Health Technol Assess. 2018. PMID: 30507375 Free PMC article. Clinical Trial.
Despite suboptimal compliance, improvements in BPRS scores at 12 weeks were 7.7 points (95% CI 3.8 to 11.5 points) greater with amisulpride than with placebo (11.9 vs. 4.2 points; p = 0.0002). In stage 2, BPRS scores improved by 1.1 point in those who continued with amisul …
Despite suboptimal compliance, improvements in BPRS scores at 12 weeks were 7.7 points (95% CI 3.8 to 11.5 points) greater with amisulpride …
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.
Banerjee S, Farina N, Henderson C, High J, Stirling S, Shepstone L, Fountain J, Ballard C, Bentham P, Burns A, Fox C, Francis P, Howard R, Knapp M, Leroi I, Livingston G, Nilforooshan R, Nurock S, O'Brien J, Price A, Thomas AJ, Swart AM, Telling T, Tabet N. Banerjee S, et al. Health Technol Assess. 2023 Oct;27(23):1-108. doi: 10.3310/VPDT7105. Health Technol Assess. 2023. PMID: 37929672 Free PMC article. Clinical Trial.
Mean difference placebo-mirtazapine (-1.74, 95% confidence interval -7.17 to 3.69; p = 0.53). Harms: The number of controls with adverse events (65/102, 64%) was similar to the mirtazapine group (67/102, 66%). ...Post hoc analysis suggests this was of marginal statistical …
Mean difference placebo-mirtazapine (-1.74, 95% confidence interval -7.17 to 3.69; p = 0.53). Harms: The number of controls with adve …
20 results